Jardiance Met 12.5mg/1000mg (Empagliflozin/Metformin)

Product Overview

Jardiance Met 12.5mg/1000mg represents a fixed‑dose combination tablet that unites two pharmacologically distinct agents Empagliflozin and Metformin in a single daily pill. The product is manufactured by Boehringer Ingelheim India Pvt Ltd a globally recognized pharmaceutical company with a strong track record in diabetes research. Each strip contains ten film‑coated tablets that are designed for optimal bioavailability and patient compliance. The available pack sizes of thirty sixty and ninety tablets allow clinicians to tailor the supply to the duration of therapy required for each patient. This formulation is specifically indicated for adults diagnosed with Type 2 diabetes mellitus who have not achieved adequate glycemic control through lifestyle modification alone and who may benefit from an additional pharmacologic option that targets multiple pathophysiologic pathways. The medication is supplied in a discreet strip packaging that facilitates easy dosing and helps maintain treatment continuity across refill cycles.

What is Jardiance Met 12.5mg/1000mg

The active ingredients in Jardiance Met are Empagliflozin a selective SGLT2 inhibitor and Metformin a biguanide that reduces hepatic glucose output. Empagliflozin works by blocking the reabsorption of glucose in the proximal kidney tubules which leads to increased urinary excretion of sugar and a consequent drop in circulating blood glucose levels. Metformin functions primarily by decreasing gluconeogenesis in the liver and improving peripheral insulin sensitivity in muscle and adipose tissue. The fixed‑dose ratio of 12.5mg Empagliflozin to 1000mg Metformin ensures that patients receive a balanced exposure to both mechanisms without the need to take separate tablets. This combination is presented as a single tablet strength that simplifies the dosing regimen and reduces the risk of missed doses. The product is marketed under the brand name Jardiance Met and is identified by its strength notation 12.5mg/1000mg reflecting the amount of each active component per tablet.

Uses and Benefits

Clinicians prescribe Jardiance Met to lower hyperglycemia in adults with Type 2 diabetes mellitus who require additional pharmacologic control beyond oral monotherapy or who are transitioning from another antidiabetic agent. The combination offers several clinically relevant benefits including superior glycemic lowering compared with either component alone a reduced risk of cardiovascular hospitalization and a modest contribution to body weight reduction. Because the tablet delivers both agents simultaneously it improves adherence and may enhance long‑term disease management. In addition the regimen can be used in patients who have tolerance issues with higher doses of Metformin alone and who need a complementary mechanism of action. The once‑daily dosing schedule aligns with typical patient routines and supports sustained therapeutic efficacy when combined with appropriate diet and exercise counseling.

How It Works

The mechanism of action of Jardiance Met leverages two complementary pathways that regulate glucose homeostasis. Empagliflozin inhibits the SGLT2 protein located in the renal proximal tubule which prevents glucose from being re‑absorbed back into the bloodstream. As a result excess glucose is eliminated through urine which not only lowers plasma glucose but also provides a diuretic effect that can modestly reduce blood pressure. Metformin activates AMP‑activated protein kinase in liver and peripheral tissues which leads to decreased gluconeogenic enzyme expression and increased glucose uptake by muscle cells. The synergistic interaction of these pathways results in a more comprehensive reduction of fasting and post‑prandial glucose levels while also addressing insulin resistance. This dual approach enables patients to achieve target A1C values more reliably and may reduce the need for additional glucose‑lowering agents over time.

Dosage Guidelines

The recommended initial dosing of Jardiance Met is one tablet administered orally once daily with the evening meal to minimize the likelihood of gastrointestinal upset. The tablet should be swallowed whole with a full glass of water and should not be crushed or split. Dosage adjustments are guided by the patient’s estimated glomerular filtration rate eGFR and by the degree of glycemic control observed during follow‑up visits. Patients with an eGFR of thirty milliliters per minute per 1.73 square meters or lower should not receive the medication due to an increased risk of accumulation and adverse renal events. In patients with stable renal function the dose may be titrated upward based on therapeutic response but should not exceed the prescribed daily amount. The appropriate pack size is selected by the prescribing clinician according to the duration of therapy and the patient’s treatment plan. It is essential that patients adhere strictly to the dosing schedule and that they consult their healthcare provider before making any changes to the regimen.

Side Effects

Like all prescription medications Jardiance Met may be associated with a range of adverse effects that vary in frequency and severity. The most commonly reported side effects include genital mycotic infections urinary tract infections and mild episodes of dizziness that are often related to volume depletion from increased urinary glucose loss. Some patients may experience a transient increase in serum creatinine which typically resolves without discontinuation of therapy. Rare but serious complications can involve diabetic ketoacidosis and acute kidney injury particularly in individuals with pre‑existing renal impairment or those who become dehydrated. For detailed scientific insight into SGLT2 inhibition readers can refer to the NIH resource NIH. Patients are advised to monitor for signs of infection such as redness irritation or unusual discharge and to report persistent or worsening symptoms to their physician promptly.

Warnings and Precautions

Prior to initiating treatment with Jardiance Met clinicians should conduct a thorough assessment of renal function liver function and history of pancreatitis. The medication is contraindicated in patients who have a known hypersensitivity to Empagliflozin Metformin or any excipients present in the formulation. Concomitant use with other investigational antidiabetic drugs or with medications that increase the risk of hypoglycemia requires careful monitoring of blood glucose levels. Patients should be instructed to maintain adequate hydration especially in hot weather or during periods of illness that may lead to reduced fluid intake. Alcohol consumption should be moderated as excessive intake can elevate the risk of lactic acidosis when combined with Metformin. Additionally the use of Jardiance Met during pregnancy or breastfeeding is not recommended and alternative therapies should be considered. Always discuss any changes to the medication regimen with a qualified healthcare professional to ensure safety and efficacy.

FAQs

Q: How many tablets are in each strip? A: Each strip contains ten tablets of Jardiance Met 12.5mg/1000mg.

Q: Can the tablet be split or crushed? A: No the tablet should be swallowed whole and should not be split or crushed.

Q: Is Jardiance Met safe for patients with kidney disease? A: It is not recommended for patients with an eGFR below thirty milliliters per minute per 1.73 square meters.

Q: Does the medication cause weight loss? A: Some patients experience modest weight loss as a result of increased glucose excretion.

Q: Where can I find more detailed prescribing information? A: Detailed prescribing information is available on the FDA label and on MedlinePlus MedlinePlus.

Related Products

• Afatinib Dimaleate 20 mg (Generic)
• Afatinib Dimaleate 30 mg (Generic)
• Afatinib Dimaleate 40 mg (Generic)
• Afatinib Dimaleate 50 mg (Generic)
• Cyendiv 100 mg (Nintedanib)
• Cyendiv 150 mg (Nintedanib)
• Xovoltib (Afatinib Dimaleate)
• Xovoltib 20 mg (Afatinib Dimaleate)
• Xovoltib 30 mg (Afatinib Dimaleate)
• Xovoltib 40 mg (Afatinib Dimaleate)
• Xovoltib 50 mg (Afatinib Dimaleate)
• Nintedanib 150 mg (Generic)